By Associate Professor Marianne Kate Martinello

Conference Papers

Lamoury F; Bajis S; Hajarizadeh B; Marshall A; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing D; Kleman M; Cunningham P; Dore G; Applegate T; Grebely J, 2018, 'THU-093 Evaluation of the Xpert fingerstick HCV viral load assay', in Journal of Hepatology, Elsevier, pp. s167, http://dx.doi.org/10.1016/s0168-8278(18)30546-4

Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2014, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 425 - 434, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP3035

Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2014, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 127 - 132, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.3851/IMP2984

Conference Presentations

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'THU-232 The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', http://dx.doi.org/10.1016/s0168-8278(17)30899-1

Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016

Conference Abstracts

Hajarizadeh B; George J; Levy M; Wong I; Howell J; Cabrera G; Tu E; Martinello M; Applegate T; Matthews G, 2024, 'Evaluation of a novel hepatitis B DNA test from fingerstick capillary blood at the point-of-care as a tool to enhance clinical management', in JOURNAL OF HEPATOLOGY, ELSEVIER, ITALY, Milan, Vol. 80, pp. S776 - S776, presented at European-Association-for-the-Study-of-the-Liver Congress (EASL), ITALY, Milan, 05 June 2024 - 08 June 2024

Bin Usman Shah SH; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Innes H; Dore G, 2022, 'FRI339 Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets', in Journal of Hepatology, Elsevier, Vol. 77, pp. s560, http://dx.doi.org/10.1016/s0168-8278(22)01443-x

Bin Usman Shah SH; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Dore G, 2022, 'THU415 Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study', in Journal of Hepatology, Elsevier, Vol. 77, pp. s302, http://dx.doi.org/10.1016/s0168-8278(22)00971-0

Hosseini-Hooshyar S; Alavi M; Martinello M; Matthews G; Dore G, 2021, 'Evaluation of the HCV cascade of care among people with HIV/hepatitis C co-infection in New South Wales, Australia: a data linkage study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 24, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713652900036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews G; Bhagani S; Van der Valk M; Rockstroh JK; Kim AY; Thurnheer C; Feld JJ; Bruneau J; Gane EJ; Hellard M; Grebely J; Applegate T; Marks P; Martinello M; Petoumenos K; Dore G, 2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000500824000056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthew G, 2019, 'Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E734 - E734, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018

Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017

Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'FRI-194 DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in Journal of Hepatology, Elsevier, Vol. 66, pp. s495 - s496, http://dx.doi.org/10.1016/s0168-8278(17)31388-0

Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'FRI-184 Incidence of HCV Reinfection among Treated Individuals with Recently Acquired Infection', in Journal of Hepatology, Elsevier, Vol. 64, pp. s620 - s621, http://dx.doi.org/10.1016/s0168-8278(16)01152-1

Reports

Bajis S; Dore G; Alavi M; McGregor S; Kwon A; Monaghan R; Iversen J; Martinello M; Buckland G; Guy R; Kaldor J; Grebely J, 2021, Progress towards hepatitis C elimination among Aboriginal and Torres Strait Islander people in Australia: monitoring and evaluation report, The Kirby Institute, UNSW Sydney, Sydney, Australia, https://kirby.unsw.edu.au/report/progress-towards-hepatitis-c-elimination-among-aboriginal-and-torres-strait-islander-people

Bajis S; Bull R; Causer L; Kaldor J; Legrand N; Martinello M; McGregor S; Naruka E; Ronnachitand A; Valencia Arroyo B; Low N, 2020, Human T-lymphotropic virus type 1: technical report, World Health Organization, Geneve, https://apps.who.int/iris/handle/10665/339773

Theses / Dissertations

Hosseini Hooshyar S; Matthews G; Dore G; Martinello M, 2022, Hepatitis C elimination among people living with HIV, http://dx.doi.org/10.26190/unsworks/24455

Preprints

Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Group RS, 2022, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248

Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, 2021, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916

Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson S; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer D; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA, 2021, Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses, http://dx.doi.org/10.2139/ssrn.3920641

Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd AR; Martinello M; Bull RA; Group CS, 2020, Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2, http://dx.doi.org/10.2139/ssrn.3732365

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2018, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607

Baird S; Ashley CL; Marsh-Wakefield F; Alca S; Ashhurst TM; Ferguson AL; Lukeman H; Counoupas C; Post JJ; Konecny P; Bartlett A; Martinello M; Bull RA; Lloyd A; Grey A; Hutchings O; Palendira U; Britton WJ; Steain M; Triccas JA, A unique cytotoxic CD4+ T cells signature defines critical COVID-19, http://dx.doi.org/10.1101/2023.02.17.23286059

Rouet R; Henry JY; Johansen MD; Sobti M; Balachandran H; Langley DB; Walker G; Lenthall H; Jackson J; Ubiparipovic S; Mazigi O; Schofield P; Burnett DL; Brown SHJ; Martinello M; Hudson B; Gilroy N; Post JJ; Kelleher A; Jäck H-M; Goodnow CC; Turville SG; Rawlinson WD; Bull RA; Stewart AG; Hansbro PM; Christ D, Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients, http://dx.doi.org/10.1101/2022.10.19.512954

Carson JM; Barbieri S; Verich A; Tu E; Lloyd A; Dore GJ; Matthews GV; Martinello M, Development of a machine learning model to predict short duration HCV treatment response, http://dx.doi.org/10.1101/2025.09.19.25336147

Bull R; Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post J; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd A; Martinello M, Long-term persistence of neutralizing memory B cells in SARS-CoV-2, http://dx.doi.org/10.21203/rs.3.rs-92527/v1

Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Bartlett AW; Ahlenstiel G; Grubor-Bauk B; Dwyer D; Konecny P; Lloyd AR; Martinello M; Bull RA; Tedla N, Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection, http://dx.doi.org/10.1101/2021.12.21.473774

Nyein PP; Haskelberg H; Martinello M; Lowe M; Goodman-Meza D; Avihingsanon A; Kelleher AD; Rodgers A; Schutte AE; Nnakelu EC; Byakwaga H; Trevillyan J; Losso M; Kumarasamy N; Azwa RISR; Kaplan R; Clifton B; Arnott C; Dharan NJ; Petoumenos K; Matthews GV, Optimizing Metabolic Management on Integrase-based ART (OPTIMAR): study protocol for a 2x2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk, http://dx.doi.org/10.21203/rs.3.rs-7648678/v1

Back to profile page